Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand93.71M Perf Week-21.18%
Market Cap316.86M Forward P/E- EPS next Y-3.79 Insider Trans- Shs Float- Perf Month-73.99%
Income- PEG- EPS next Q- Inst Own0.06% Short Float- Perf Quarter-61.40%
Sales- P/S- EPS this Y66.80% Inst Trans- Short Ratio0.65 Perf Half Y-60.86%
Book/sh-3.35 P/B- EPS next Y-57.26% ROA- Short Interest0.01M Perf Year-
Cash/sh0.64 P/C5.28 EPS next 5Y- ROE- 52W Range3.31 - 19.30 Perf YTD-62.39%
Dividend Est.- P/FCF- EPS past 5Y-90.91% ROI- 52W High-82.48% Beta-
Dividend TTM- Quick Ratio0.16 Sales past 5Y-25.00% Gross Margin- 52W Low2.15% ATR (14)1.29
Dividend Ex-DateAug 13, 2008 Current Ratio0.16 EPS Y/Y TTM- Oper. Margin- RSI (14)20.86 Volatility18.73% 20.02%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price30.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q- Payout- Rel Volume0.35 Prev Close3.60
Sales Surprise0.00% EPS Surprise-150.34% Sales Q/Q- Earnings- Avg Volume16.57K Price3.38
SMA20-60.64% SMA50-68.25% SMA200-65.27% Trades Volume5,749 Change-6.07%
Date Action Analyst Rating Change Price Target Change
Oct-24-23Initiated Cantor Fitzgerald Overweight $30
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.